Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
P/S ratio for Celltrion, Inc. (068270.KS)
P/S ratio as of 2023: 14.44
According to Celltrion, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 14.44. At the end of 2022 the company had a P/S ratio of 9.24.
P/S ratio history for Celltrion, Inc. from 2007 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 14.44 |
| 2022 | 9.24 |
| 2021 | 13.74 |
| 2020 | 25.21 |
| 2019 | 20.39 |
| 2018 | 26.46 |
| 2017 | 28.24 |
| 2016 | 18.72 |
| 2015 | 15.79 |
| 2014 | 9.05 |
| 2013 | 18.60 |
| 2012 | 4.17 |
| 2011 | 14.29 |
| 2010 | 19.69 |
| 2009 | 10.12 |
| 2008 | 11.09 |
| 2007 | 0.28 |